Deals ramp up in Asia’s healthcare space with cancer focus

An acquisition in Hong Kong by the New Frontier Group, an IPO by Sunho Biologics on the HKEX and a $1.5bn investment into Singapore by AstraZeneca, are signs that investments in next generation cancer treatments are increasing in the region.

There have been several high profile deals and developments in Asia’s cancer treatment space over the last few weeks, showing the growing interest a range of investors have in the region's healthcare sector. 

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media